Background and Purpose: This study aimed to assess the sensitivity and specificity of brain stem morphologic changes to differentiate the progressive supranuclear palsy (PSP) from Parkinson disease (PD) and multiple system atrophy (MSA), by single and combined magnetic resonance imaging (MRI) measurements. Materials and Methods: Peduncle angle (PA), pons area (P), mesencephalon area (M), middle cerebellar peduncles (MCPs), and superior cerebellar peduncles (SCPs) were measured in 14 PSP, 43 PD, 8 MSA patients, and 45 age-matched control participants on T1-weighted MRI. Neurologists clinically diagnosed all patients. Additionally, P/M ratio, MCPs/SCPs ratio, the previously defined Magnetic Resonance Parkinsonism Index, MRPI: (P/M) Á (MCP/SCP), and also the Akdeniz Index (AKI) that we termed were calculated, AKI: (P/M) Á (PA/180). Two blinded radiologists evaluated all MR images and inter-/intraobserver variations were measured. Results: Both M and SCPs were significantly lower and P/M, MCPs/SCPs, and PA were significantly higher in PSP patients than the other groups (P < .001). This significance was related to patients with PSP and PD. But all single measurements showed some overlapping values. Therefore, previously defined MRPI was calculated and shown to distinguish patients (negative predictive values: 92%, sensitivity: 78%, specificity: 82%). In this study, interobserver correlation (0.68) was found low for MRPI. Therefore, we identified a more practical index: the Akdeniz Index, which has same diagnostic power with MRPI and higher interobserver correlation (0.91). Conclusion: The Akdeniz Index identified in our study is a practical index with high diagnostic power and can reinforce radiological distinguishing of PSP and PD, which are clinically difficult to distinguish. Résumé Contexte et objectif : Cetteétude avait pour objectif d'évaluer la sensibilité et la spécificité des modifications morphologiques du tronc cérébral pour différencier la paralysie supranucléaire progressive (PSP) de la maladie de Parkinson (MP) et de l'atrophie multisystématisée (AMS) par des mesures réalisées par imagerie par résonance magnétique (IRM) simples ou combinées. Matériel et méthodes : L'angle interpédonculaire (AIP), l'aire du pont (P), l'aire du mésencéphale (M), les pédoncules cérébelleux moyens (PCM) et les pédoncules cérébelleux supérieurs (PCS) ontété mesurés par IRM pondérée en T1, chez d'une part 14 patients atteints de PSP, 43 souffrant de la MP et 8 présentant une AMS, et d'autre part chez 45 participants témoins d'âge correspondant. Les neurologues ont posé un diagnostic clinique chez tous les patients. Par ailleurs, le rapport P/M, le rapport PCM/PCS et l'indice parkinsonien précédemment défini par imagerie par résonance magnétique [IPRM ¼ (P/M) Â (PCM/PCS)], ainsi que l'indice de Akdeniz (Akdeniz Index; AKI) que nous avons défini [AKI ¼ (P/M) Â (AIP/180)], ontété calculés. Deux radiologistes ont analysé en aveugle l'ensemble des clichés d'IRM. Les variations inter-et intra-évaluateurs ont ensuiteété mesurées. Résultats : Les valeurs M et PCSétaient significativement inférieures et les valeurs P/M, PCM/PCS et AIPétaient significativement supérieures chez les patients atteints de PSP par rapport aux autres groupes (P < 0,001). Ces différences significativesétaient associées aux patients atteints de PSP et de MP. Cependant, toutes les mesures simples ont présenté des valeurs chevauchantes. Ainsi, l'IPRM précédemment défini aété calculé et a permis de différencier les divers types de patients (valeurs prédictives négatives de 92 %, sensibilité de 78 % et spécificité de 82 %). Dans cetteétude, la corrélation inter-évaluateurs obtenue (0,68)était faible pour l'IPRM. Par conséquent, nous avons identifié un indice plus pratique : l'indice de Akdeniz qui a le même
Introduction
Parkinson disease (PD) is a progressive neurodegenerative that mainly affects the motor system. The most prominent motor symptoms are characterized by tremor, rigidity, bradykinesia, postural instability, and collectively termed ''parkinsonism.'' Parkinson plus syndrome term defines a group of neurodegenerative diseases characterized by the classical features of parkinsonism with additional features that distinguish them from simple PD.
Multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are both neurodegenerative diseases that are types of Parkinson plus syndromes. 1 Progressive supranuclear palsy is characterized by speech disturbances, cognitive impairment, postural instability and falls, abnormal eye movements (typically supranuclear vertical gaze palsy), and parkinsonism. 2, 3 Multiple system atrophy is characterized by parkinsonism, various degrees of autonomic dysfunction, cerebellar abnormalities, and corticospinal degeneration. 4 Distinguishing of PSP from PD and MSA can be challenging, especially in the early stages of the disease. 5, 6 Clinic distinction is challenging among these entities but important because each disease has very different therapeutic approaches. Especially, this distinction is essential for patients with PSP because PSP has a worse prognosis than the others, surgical interventions such as deep brain stimulation are unhelpful, and response to medical treatment is limited. Therefore, a simple and straightforward method is necessary to differentiate this disorder.
Magnetic resonance imaging (MRI) studies on PSP, MSA, and PD have shown that MRI features in the brain stem match with histopathological findings. Superior cerebellar peduncles (SCPs) and midbrain atrophy have been found in PSP, 2,7-9 whereas middle cerebellar peduncles (MCPs) and pons atrophy have been found in MSA. 7, [9] [10] [11] Unlike these, all these brain structures are preserved in PD.
In addition to routine MRI, volumetric MRI, diffusionweighted MRI, and magnetic resonance (MR) spectroscopy were used to confirm the diagnostic value of midbrain atrophy in PSP. However, the methods varied widely and include subjective estimates or measurement of some single or combined brain structures like peduncle angle (PA), SCP, mesencephalon area (M), and so on.
This study aimed to assess the sensitivity and specificity of brain stem morphologic changes distinguishing patients with PSP from patients with PD and MSA, by single and combined MRI measurements. Based on this data, assess the diagnostic power of previously defined MR Parkinsonism Index and index that we termed the ''Akdeniz Index''.
Methods

Patient Selection
Magnetic resonance images of the patients and the control group were evaluated retrospectively after the approval of the local ethics committee. The records of 132 patients admitted to the Neurology Department, Movement Disorder Clinic between November 2015 and May 2017 were retrospectively reviewed. Patients with additional cerebral pathology such as secondary parkinsonian disorders (medicine related, vascular, trauma, mass), heredodegenerative diseases (Alzheimer disease, Wilson disease), and additional cerebral pathology at MRI (hydrocephalus, infarction, subdural effusion and hemorrhage, deep brain stimulation operation history) were excluded from the study. And also 2 patients with MSA, 3 patients with PSP, and 5 patients with PD were excluded because of the motion artifacts. After patients with additional cerebral pathologies and artifacts have been removed, 14 patients with probable PSP, 43 with PD, and 8 with MSA were evaluated. The diagnosis of the patients has been established by a neurologist with experience in movement disorders for more than 15 years. And patients' diagnosis were established according to clinical diagnostic criteria, independently from MR reports. In this study, patients were included only if they fully fulfilled the recommended criteria for each disease.
In addition to the patient group, 45 age-matched healthy control participants were evaluated. The healthy control participants were from patients with normal MRI which were performed for headache or dizziness, and they had no history of head trauma, surgery, or any other central nervous system disorder. Patients with motion or susceptibility artifact in MR images were also excluded from the study.
Image Acquisition
Magnetic resonance images were performed by 3 T wholebody system (Spectra; Siemens-Healthcare, Germany). The MRI examination protocol had a 3D T1 Magnetization Prepared -RApid Gradient Echo (MPRAGE) sequence (Repetition time/echo time, 1900/2.41; matrix, 256 Â 189; field of view, 270 mm; slice thickness, 1 mm with no gap; flip angle, 9 ; number of axial slices, 176; acquisition time, 3 minutes 48 seconds) through the whole brain. Three-dimensional T1-MPRAGE images were postprocessed for measuring the brain stem structures. All images were examined on the workstation using the 3D-MPR option in the Sectra (IDS 7, 18.2; Linköping, Sweden) imaging program.
Image Evaluation
Two independent radiologists (one observer was an experienced neuroradiologist, who had a 20 years of MRI experience, the other observer was a last year resident who has a 5 years of radiology experience) who were blinded to the patients' diagnoses evaluated all MR images. Thus, interobserver reliability was also established. Besides, after 2 weeks, a second evaluation was made by one of the researchers to assess the intraobserver reliability.
The pons area (P), M, middle peduncle widths (MCPs) mean value, superior peduncle widths (SCPs) mean value, and PA were measured from 3D T1-MPRAGE images. In addition to this the P/M ratio, MCPs/SCPs ratio, the previously defined Magnetic Resonance Parkinsonism Index, 12 MRPI: (P/M) Á (MCPs/SCPs), and also index that we termed the ''Akdeniz Index'' were calculated, Akdeniz Index: (P/M) Á (PA/180).
The P and M have measured on midsagittal images for all participants as described by Oba et al. 13 Firstly, we drew 2 straight lines: above, a line passing through the superior pontine notch and inferior edge of the quadrigeminal plate; below, a line which is parallel to the first line and passes through the inferior pontine notch ( Figure 1 ). The area of the mesencephalon tegmentum was measured from the area above the first line and P was measured among the 2 lines along the posterior and anterior edge of the pons, as shown in Figure 1 .
The MCPs were measured on midsagittal images in all patients and control participants as described by Nicoletti et al. 11 Midsagittal section of the brain MR image was chosen as the reference and left/right middle peduncles were identified on parasagittal views that are best visualized ( Figure 1 ). The linear distance among the superior and inferior edges of both middle peduncle widths was measured and the mean value was calculated. The SCPs were measured on the oblique coronal volumetric T1WI as described by Quattrone et al. 12 Sections were viewed in the anteroposterior projection and inferior colliculi and superior peduncles were identified. The thickness among the medial and lateral borders of both superior peduncle widths was measured at the middle of superior peduncle length, as shown in Figure 1 .
The PA was measured as described by Fatterpekar et al. 14 Measurements were standardized according to this description. Firstly, the 3D axial T1-weighted image was reformatted along the posterior-anterior commissure line (straight line on Figure 2 ). Then for the measurement of the cerebral PA, axial plane was chosen as just below the mammillary bodies (dashed line on 
Statistical Analysis
Statistical analysis was performed with statistical software (SPSS for Windows, version 23.0; SPSS, Chicago, Illinois). Kolmogorov-Smirnov test was used for testing normality of the quantitative data. Non-normally distributed data were compared with nonparametric Kruskal-Wallis H and Mann-Whitney U tests. Normally distributed data were compared with parametric independent t test. The Kruskal-Wallis test was used to evaluate the differences in MRI measurements between groups and then Mann-Whitney U was used for multiple comparisons. P value results were corrected by Bonferroni method. The intraclass correlation coefficient was calculated to verify the interobserver and intraobserver reliability. For the test correlations between MRI measurements and clinical variables, Spearman coefficient was calculated. Sensitivity, specificity, negative predictive value (NPV), and area under the curve (AUC) were calculated by using the optimal cutoff values determined by using receiver operating characteristic (ROC) curve analysis. The values that had the highest sum of sensitivity and specificity were considered optimal cutoff levels. In statistical analyses, P < .05 was considered significant.
Results
Measurements for P, M, MCPs, SCPs, and PA are shown in Table 1 . Measurements for SCPs and M were lower and PA was higher in patients with PSP than in patients with MSA, patients with PD, and control participants ( Table 1, Figures 3  and 4 ). Besides there was a significant negative correlation among M and PA. Measurements for MCPs and P were lower in patients with MSA than in the other groups ( Figure 5 ). Despite this, in patients with PD, there was no difference between control participants for any measurement (Table 1) .
There was a statistically significant difference among the measurements for patients with PSP, MSA, and PD (P < .05), except MCPs. However, MCPs were very close to significance value (P ¼ .06). Pairwise comparisons showed that the significance was due to the difference between patients with PSP and PD ( Table 2) .
Evaluations of Combined Measurements
The P/M values: P/M values (median, 4.09; range, 2.70-5.84) were significantly lower in patients with PSP than in patients with PD (median, 5.51; range, 3.45-8.72; P < .0001). To distinguish patients with PSP, the specificity and sensitivity values of P/M ratio were calculated and the optimal cutoff level was found to be 4.51 or greater by ROC analysis. Although the average measurement of patients with PSP was significantly lower, individual values of patients with PSP overlapped with values in the other groups of patients ( Figure 6 ) and specificity and sensitivity values were slightly low (Table 3 ). There was no difference among patients with PD and control participants.
The MCPs/SCPs values: MCPs/SCPs values (median, 3.02; range, 2.55-4.71 (median, 2.57; range, 1.90-3.54) were significantly higher in patients with PSP than in patients with PD (median, 2.57; range, 1.90-3.54; P < .0001). To distinguish patients with PSP, the specificity and sensitivity values of MCPs/SCPs ratio were calculated and the optimal cutoff level was found to be 2.79 or greater by ROC analysis. But there was some overlap of individual values among all groups ( Figure 6 ) and specificity and sensitivity values were slightly low ( Table 3) .
The MRPI values: In patients with PSP, the index was significantly higher in parallel with the results mentioned earlier. There were significant differences between patients with PSP and PD (P < .0001) and there was less overlap of individual values than single measurements. There was not a significant difference between PSP-MSA and PD-MSA patients. The sensitivity, specificity, and NPV of the MRPI were calculated to differentiate patients with PSP from patients with PD, and cutoff values were determined by ROC analysis. Optimal cutoff level was 13.3 or higher ( Table 4 ).
The AKI values: In patients with PSP, AKI was significantly higher, and there was a significant difference between patients with PSP and PD (P < .0001). The sensitivity, specificity, and NPV of the AKI were calculated to differentiate patients with PSP from patients with PD, and the cutoff values were determined by ROC analysis. Optimal cutoff level was 2.21 or higher ( Table 4 ).
The ROC analysis was performed for both indexes. The AUCs were 0.87 (95% confidence interval: CI, 0.69-0.97) for the MRPI and 0.83 (95% CI, 0.76-0.99) for the AKI to differentiate patients with PSP from patients with PD (Table 4, Figure 7 ).
Interobserver and intraobserver correlations for MRPI and AKI were evaluated. For the MRPI, interobserver correlation was 0.68 and the intraobserver correlation was 0.98, and for the AKI, interobserver correlation was 0.91 and the intraobserver correlation was 0.98, as shown in Table 4 . 
Discussion
Atrophy of the midbrain is a typical neuropathologic feature in PSP. 14, 15 Most MRI studies 14, [16] [17] [18] [19] [20] [21] confirm the diagnostic value of midbrain atrophy in PSP, but the methods varied the range of subjective estimation to objective criteria. Moreover, some of these methods are not reproducible and practical.
In our study, MRI findings confirmed the mesencephalon atrophy in patients with PSP and suggested that the measurement of the midbrain area or PA could be helpful in the distinguishing of PSP from the PD. In some previous studies, SCP atrophy was found on volumetric MR images similar to our study. 8 Although the PSP patients' average M and SCPs were Figures 1 and 3) . lower, and PA was higher, individual values of patients with PSP overlapped with those other groups' values. Our findings demonstrate that single brain structure measurement failed to differentiate the patients with PSP from other groups, on an individual basis.
Oba et al 13 declared that the P/M ratio was a better measurement for the distinguishing of patients with Parkinson plus syndromes from patients with PD and control group. We calculated this ratio in our study and the cutoff value was calculated by using ROC analysis. However, the sensitivity and specificity values of this ratio were relatively low and the values were overlapping ( Figure 6 ).
In a previous study, 12 MCPs/SCPs ratio was evaluated and it was demonstrated that the MCPs/SCPs was considerably higher in patients with PSP than patients with PD. We also found similar results in our study, but sensitivity and specificity values of these ratios were relatively low and it was observed that the values were overlapping like the P/M ratio. Besides, the low level of SCPs's interobserver correlation was remarkable ( Table 5) .
Quattrone et al suggested to use a combined MRI assessment that involved 4 brain structures (P and MCPs suggests MSA, whereas M and SCPs suggest PSP) to distinguish patients from each other. 12 In this study, they calculated an index called as MRPI, MRPI: (P/M) Á (MCPs/SCPs). Their results showed that MRPI was significantly higher in patients with PSP (median, 19.42) than in patients with PD (median, 9.40; P < .001), patients with MSA (median, 6.53; P < .001), and control participants (median, 9.21; P < .001). They concluded MRPI allowed to distinguish patients with PSP from patients with PD, patients with MSA, and control participants on an individual basis with 100% specificity, 100% sensitivity, and 100% PPV. We didn't obtain similar results for MRPI in our study. But when we use the approximate levels for the MRPI, we got better results than single brain structure measurements for distinguishing patients with PSP from patients with PD. Differently, we didn't obtain significant results for distinguishing patients with PSP from patients with MSA and this may be due to the low number of patients. However, when interobserver and intraobserver correlations for MRPI were evaluated, values were found to be low and it was probably due to the small size of the SCPs and the difficulty of measurement plane standardization (Table 5 ).
To overcome this problem, we defined a new index, which magnifies the effect of the PA and omits the difficult measurements of the SCPs and MCPs. We named it as ''AKI,'' (P/M) Á (PA/180), and we believe that AKI is more practical and has a higher agreement between observers.
The ROC analysis was performed for both indexes, and sensitivity, specificity, diagnostic accuracy, AUC, and NPV values were calculated. We obtained close similar values of sensitivity, specificity, diagnostic accuracy, NPV, and AUC for both; 13.63 and higher values of MRPI and 2.21 and higher values of AKI (Table 4, Figure 7 ). The NPVs of MRPI and AKI in distinguishing patients with PSP from PD were found to be 92% and with both indexes showed that patients who don't have PSP were more likely to have PD. Unlike MRPI in AKI, the interobserver correlation was found to be quite high. We also found that the AKI was insufficient to differentiate patients with MSA. We attributed this situation to the low number of patients with MSA and the magnification effect of mesencephalon atrophy by using P and M measurements in the defined index and to minimize the effect of pons atrophy in patients with MSA.
Both AKI and MRPI facilitate distinguishing patients with PSP from those with PD. However, because of the practicality, easy measurement standardization, high reproducibility, and interobserver correlations, we believe that AKI could be preferable than MRPI in daily practice.
There were some limitations to this study. We did not have pathologic confirmation, so diagnoses were confirmed clinically. But, in this study, all patients were evaluated by one of the authors who has experience on movement disorders more than 15 years and all patients were included only when they fully fulfilled the recommended criteria for each disease. The most important limitation of our study was being retrospective. Because of the retrospective evaluation, the duration of the diseases after diagnosis could not be standardized. But the diseases in our study, especially PSP and MSA, are rare, and therefore, we had to include all patients who fit the diagnostic criteria during the study period. Survey in PSP and MSA is relatively short and their early diagnosis is usually not possible because the symptoms are common in other movement disorders. We also had to exclude the patients if the diagnostic criteria are not fully fit and who are most probably in the early stages of the disease. Therefore, we believe that the patients in our study are in mid or advanced stages of their diseases. Quattrone et al's study implies that anatomical changes in the brain stem structures may be related to clinical stage of those diseases or progression of the clinical status. It should be emphasized that the diagnoses of the movement disorders are made clinically. The measurements may only be helpful in clinically undetermined cases with vague symptoms. The retrospective studies may provide basis for prospective evaluation of the patients with movement disorders. A measurement in the initial presentation and follow-up of the patient for a considerable time like 5 years may provide much reliable data about the efficiency of the measurements and indices. A prospective study may define the predictive values of AKI in the early stage of the disease and disease progression. 
